Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

(2010) James R. Perry et al.   JOURNAL OF CLINICAL ONCOLOGY

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

(2010) Richard M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

(2009) Annamaria Rapisarda et al.   DRUG RESISTANCE UPDATES

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule

(2008) James R. Perry et al.   CANCER

Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib

(2008) Przemyslaw W. Twardowski et al.   CANCER INVESTIGATION

Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells

(2008) F. Shojaei et al.   CANCER RESEARCH

Tumor Escape from Endogenous, Extracellular Matrix-Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors

(2008) N. T. Fernando et al.   CLINICAL CANCER RESEARCH

Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: A preliminary monocentric study

(2008) Nicolas André et al.   CLINICAL THERAPEUTICS

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib

(2008) J. Ma et al.   MOLECULAR CANCER THERAPEUTICS

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

(2008) B. Laquente et al.   MOLECULAR CANCER THERAPEUTICS

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors

(2007) L. Mi Rim Choi et al.   PEDIATRIC BLOOD & CANCER